Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PErsonalized Addition of Recombinant LH in Suboptimal Responders >35 Years Old (POSEIDON Group 2): A Randomized Controlled Trial

NCT04719000 is registered in ClinicalTrials.gov with Fundación Santiago Dexeus Font as lead sponsor.

NCT NCT04719000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04719000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PErsonalized Addition of Recombinant LH in Suboptimal Responders >35 Years Old (POSEIDON Group 2): A Randomized Controlled Trial
Lead sponsor
Fundación Santiago Dexeus Font
Phase
Phase 4
Overall status
Recruiting
Start date
February 4, 2021
Completion date
November 30, 2027
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infertility